NASDAQ:ALBO - Albireo Pharma Stock Price, Forecast & News

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Albireo Pharma Inc (NASDAQ:ALBO) posted its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.55) by $0.18. The biopharmaceutical company had revenue of $1.39 million for the quarter, compared to analysts' expectations of $1.38 million. Albireo Pharma had a negative return on equity of 62.69% and a negative net margin of 1,881.86%. View Albireo Pharma's Earnings History.

Albireo Pharma is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Albireo Pharma.

Albireo Pharma will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 brokerages have issued 12 month price objectives for Albireo Pharma's shares. Their forecasts range from $39.00 to $69.00. On average, they anticipate Albireo Pharma's stock price to reach $56.67 in the next twelve months. This suggests a possible upside of 149.4% from the stock's current price. View Analyst Price Targets for Albireo Pharma.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Albireo Pharma.

Media headlines about ALBO stock have been trending extremely negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Albireo Pharma earned a media sentiment score of -4.2 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Albireo Pharma.

Albireo Pharma saw a decline in short interest in the month of February. As of February 14th, there was short interest totalling 576,500 shares, a decline of 16.3% from the January 30th total of 688,900 shares. Based on an average trading volume of 103,100 shares, the days-to-cover ratio is presently 5.6 days. Currently, 5.7% of the shares of the company are sold short. View Albireo Pharma's Current Options Chain.

Some companies that are related to Albireo Pharma include Y-mAbs Therapeutics (YMAB), Amneal Pharmaceuticals (AMRX), Revance Therapeutics (RVNC), Akebia Therapeutics (AKBA), Phibro Animal Health (PAHC), I-Mab (ARQT), Supernus Pharmaceuticals (SUPN), Rocket Pharmaceuticals (RCKT), Dermira (DERM), Enanta Pharmaceuticals (ENTA), NextCure (NXTC), Odonate Therapeutics (ODT), Kiniksa Pharmaceuticals (KNSA), Athenex (ATNX) and Portola Pharmaceuticals (PTLA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer LP Unit (ET), Heat Biologics (HTBX), CBL & Associates Properties (CBL), GW Pharmaceuticals PLC- (GWPH), Martin Midstream Partners (MMLP), Cornerstone Total Return Fund (CRF), Palatin Technologies (PTN), Exelixis (EXEL), Viking Therapeutics (VKTX) and SandRidge Permian Trust (PER).

Albireo Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (6.83%), Point72 Asset Management L.P. (1.67%), State Street Corp (1.53%), Chicago Capital LLC (1.38%), Victory Capital Management Inc. (1.20%) and Victory Capital Management Inc. (1.20%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford. View Institutional Ownership Trends for Albireo Pharma.

ALBO stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Chicago Capital LLC, Heartland Advisors Inc., Victory Capital Management Inc., Victory Capital Management Inc., Goldman Sachs Group Inc., Blair William & Co. IL and State Street Corp. Company insiders that have sold Albireo Pharma company stock in the last year include Patrick Taylor Horn and Simon NR Harford. View Insider Buying and Selling for Albireo Pharma.

ALBO stock was bought by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Point72 Asset Management L.P., Bank of Montreal Can, California Public Employees Retirement System, MAI Capital Management, Alpine Global Management LLC, Birchview Capital LP and Geode Capital Management LLC. Company insiders that have bought Albireo Pharma stock in the last two years include Perceptive Advisors Llc and Ronald Harold Wilfred Cooper. View Insider Buying and Selling for Albireo Pharma.

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALBO stock can currently be purchased for approximately $22.72.

Albireo Pharma has a market capitalization of $288.32 million and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-46,110,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis. Albireo Pharma employs 39 workers across the globe.View Additional Information About Albireo Pharma.

The official website for Albireo Pharma is http://www.albireopharma.com/.

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]